Novo Holdings A S Purchases 36,337 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Novo Holdings A S boosted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 3.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,000,000 shares of the biopharmaceutical company's stock after buying an additional 36,337 shares during the quarter. Celldex Therapeutics makes up about 1.5% of Novo Holdings A S's investment portfolio, making the stock its 18th largest position. Novo Holdings A S owned 1.51% of Celldex Therapeutics worth $25,270,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its position in Celldex Therapeutics by 23.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after acquiring an additional 676,771 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Celldex Therapeutics by 46.5% in the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock valued at $15,376,000 after buying an additional 193,093 shares in the last quarter. Eversept Partners LP raised its holdings in shares of Celldex Therapeutics by 27.4% in the fourth quarter. Eversept Partners LP now owns 719,836 shares of the biopharmaceutical company's stock valued at $18,190,000 after buying an additional 154,934 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Celldex Therapeutics during the 4th quarter worth about $3,452,000. Finally, Silverarc Capital Management LLC increased its position in Celldex Therapeutics by 82.5% in the 4th quarter. Silverarc Capital Management LLC now owns 264,560 shares of the biopharmaceutical company's stock valued at $6,685,000 after acquiring an additional 119,560 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts recently weighed in on CLDX shares. The Goldman Sachs Group lowered their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. UBS Group assumed coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 price target on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Friday, February 28th. Finally, Morgan Stanley initiated coverage on shares of Celldex Therapeutics in a research note on Thursday, March 20th. They set an "overweight" rating and a $46.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $55.30.

Celldex Therapeutics Stock Down 1.8 %

Shares of CLDX traded down $0.37 during trading hours on Monday, reaching $20.29. The stock had a trading volume of 770,173 shares, compared to its average volume of 884,528. The firm has a 50-day moving average of $19.09 and a 200 day moving average of $23.13. The company has a market cap of $1.35 billion, a P/E ratio of -7.89 and a beta of 1.39. Celldex Therapeutics, Inc. has a 52 week low of $14.40 and a 52 week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The company had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. As a group, equities analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.